5 Biotech Stocks with Huge Potential

3. Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)

Number of Hedge Fund Holders: 42

Founded in 2003, Dublin, Ireland-based Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) is a global biopharmaceutical company with a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments.

On January 29, Barclays lowered the price target for Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares to $235 from $240 and maintained an ‘Overweight’ rating for its shares. The target price represents a potential upside of 77.92%, one of the highest on our list of 10 biotech stocks with huge potential.

As of Q4 2023, Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares were owned by 42 hedge funds with the total shares held by them valued at $1.2 billion. Its largest hedge fund shareholder was Bernard Horn’s Polaris Capital Management with ownership of 1.3 million shares valued at $156 million.